Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | CPA1 | P15085 | 4/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL432795 | 1.00 | SLC7A5 (0.49) | SLC7A5CPA1FNTAFNTBPOLB | |
| SCHEMBL598436 | 0.87 | CPA1 (0.54) | SLC7A5CPA1FOLH1 | |
| SCHEMBL598437 | 0.87 | CPA1 (0.54) | SLC7A5CPA1FOLH1 | |
| SCHEMBL31480614 | 0.86 | SLC7A5 (0.47) | SLC7A5CPA1FNTAFNTBPOLB | |
| SCHEMBL31480546 | 0.84 | SLC7A5 (0.50) | SLC7A5CPA1FNTAFNTBPOLB | |
| SCHEMBL5966737 | 0.84 | SLC7A5 (0.46) | SLC7A5CPA1FNTAFNTBPOLB | |
| SCHEMBL5341495 | 0.84 | SLC7A5 (0.50) | SLC7A5CPA1FNTAFNTBPOLB | |
| SCHEMBL20856984 | 0.80 | FNTA (0.47) | SLC7A5CPA1FNTAFNTBPOLB | |
| SCHEMBL8513742 | 0.78 | OPRM1 (0.46) | SLC7A5CPA1FNTAFNTB | |
| SCHEMBL2542276 | 0.78 | SLC7A5 (0.56) | SLC7A5FNTAFNTBPOLBESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114648-B2 | In vivo incorporation of unnatural amino acids | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-02-14 | — | — | US | claimed |
| US-20080167243-A1 | immunizing a subject with a sufficient amount of a translated polypeptide to produce antibody; containing a phenylalanine or tyrosine derivative analoges | THE SCRIPPS RESEARCH INSTITUTE | 2008-07-10 | — | — | US | claimed |
| US-20180112200-A1 | COMPOSITIONS AND METHODS FOR GENERATING ANTIGENS, ANTIBODIES, AND IMMUNOTHERAPEUTIC COMPOSITIONS AND METHODS | UNIV CALIFORNIA (US) | 2018-04-26 | — | — | US | disclosed |
| EP-3237439-A1 | COMPOSITIONS AND METHODS FOR GENERATING ANTIGENS, ANTIBODIES, AND IMMUNOTHERAPEUTIC COMPOSITIONS AND METHODS | The Regents of The University of California (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170016924-A1 | METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE | UNIVERSITY OF WASHINGTON (US) | 2017-01-19 | — | — | US | disclosed |
| WO-2016106198-A1 | COMPOSITIONS AND METHODS FOR GENERATING ANTIGENS, ANTIBODIES, AND IMMUNOTHERAPEUTIC COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016018937-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING INSECT PROLIFERATION | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-02-04 | — | — | WO | disclosed |
| EP-2596124-B1 | NOVEL SUBSTRATES THE FLUORESCENCE OF WHICH IS SUPPRESSED, PREPARATION THEREOF, AND USE THEREOF FOR IDENTIFYING, DETECTING, AND ASSAYING LEGIONELLA PNEUMOPHILIA | PHARMALEADS (FR) | 2015-07-08 | — | — | EP | disclosed |
| US-20130203097-A1 | SUBSTRATES THE FLUORESCENCE OF WHICH IS SUPPRESSED, PREPARATION THEREOF, AND USE THEREOF FOR IDENTIFYING, DETECTING, AND ASSAYING LEGIONELLA PNEUMOPHILIA | PHARMALEADS (FR) | 2013-08-08 | — | — | US | disclosed |
| EP-2596124-A1 | NOVEL SUBSTRATES THE FLUORESCENCE OF WHICH IS SUPPRESSED, PREPARATION THEREOF, AND USE THEREOF FOR IDENTIFYING, DETECTING, AND ASSAYING LEGIONELLA PNEUMOPHILIA | Pharmaleads (FR) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012010668-A1 | NOVEL SUBSTRATES THE FLUORESCENCE OF WHICH IS SUPPRESSED, PREPARATION THEREOF, AND USE THEREOF FOR IDENTIFYING, DETECTING, AND ASSAYING LEGIONELLA PNEUMOPHILIA | PHARMALEADS (FR) | 2012-01-26 | — | — | WO | disclosed |
| US-20100297680-A1 | METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE | UNIVERSITY OF WASHINGTON (US) | 2010-11-25 | — | — | US | disclosed |
| US-7749729-B2 | Methods for assessing the risk for development of cardiovascular disease | UNIVERSITY OF WASHINGTON (US) | 2010-07-06 | — | — | US | disclosed |
| US-20080261250-A1 | Methods for Assessing the Risk for Development of Cardiovascular Disease | UNIVERSITY OF WASHINGTON (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1787116-A4 | METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE | UNIV WASHINGTON (US) | 2008-05-28 | — | — | EP | disclosed |
| EP-1787116-A1 | METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE | University of Washington (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006014628-A1 | METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE | UNIVERSITY OF WASHINGTON (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20040009911-A1 | Hepsin substrates and prodrugs | IRM, LLC (BM) | 2004-01-15 | — | — | US | disclosed |
| WO-2003064620-A2 | HEPSIN SUBSTRATES AND PRODRUGS | IRM, LLC (BM) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167243-A1 | immunizing a subject with a sufficient amount of a translated polypeptide to produce antibody; containing a phenylalanine or tyrosine derivative analoges | DNPEP, NPEPPS, TYR | SLC7A5 97/4885CPA1 734/4885FNTA 227/4885 |
| US-20040009911-A1 | Hepsin substrates and prodrugs | HPN, SPR, TMPRSS15 | SLC7A5 2806/4885CPA1 246/4885FNTA 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.